Pages that link to "Q37212663"

The following pages link to Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration (Q37212663):

Displaying 10 items.

• Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen (Q34092322) (← links)
• Diffusion of technologies for the care of older adults with exudative age-related macular degeneration. (Q34503375) (← links)
• Extra cellular matrix derived metabolite regulates angiogenesis by FasL mediated apoptosis (Q35063753) (← links)
• One-year outcomes using ranibizumab for neovascular age-related macular degeneration: results of a prospective and retrospective observational multicentre study (Q35585259) (← links)
• FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1 (Q37482353) (← links)
• Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome (Q38255415) (← links)
• Ranibizumab treatment administered as needed for occult and minimally classic neovascular membranes in age-related macular degeneration (Q50525128) (← links)
• Prospective study evaluating the predictability of need for retreatment with intravitreal ranibizumab for age-related macular degeneration (Q84458372) (← links)
• Characteristics of eyes with secondary loss of visual acuity receiving variable dosing ranibizumab for neovascular age-related macular degeneration (Q84497944) (← links)
• Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in germany: Model analysis from the perspective of germany's statutory health insurance system (Q84634381) (← links)